BeiGene (BeOne)
BeiGene is the first Chinese biotech to successfully commercialize a blockbuster cancer drug globally; it is currently rebranding as a Swiss company to shed geopolitical baggage.
Revenue
$3.8B
FY2024
Profitability
Unknown
Division
Healthcare and Biotech
Public
Headquarters
Basel
John V. Oyler
Operating Model
What They Do
BeiGene is a commercial stage biotechnology company focused on oncology. Its proprietary blockbuster drugs are BRUKINSA and TEVIMBRA.
Who They Serve
Moat: Where They Win
Best in Class Efficacy
Brukinsa proved mathematically superior to Imbruvica in head to head clinical trials.
Clinical Trial Engine
Operates its own massive internal clinical team to accrue data faster and cheaper.
Geopolitical Agility
Redomiciled its corporate headquarters to Switzerland in 2025.
Business Model
Model Type
Revenue Streams
Profitability
Status
Unknown
Revenue
$3.8B
FY2024
Division
Healthcare and Biotech
Public
Margin Profile
Achieved GAAP profitability in early 2025 as global sales of BRUKINSA scaled past its massive multi year R&D burn.
Catalyst: Why Now
BeiGene has finally crossed the biotech Valley of Death. It is no longer a speculative startup; it is a cash generating pharma major.
Competitive Landscape
* Competitive threat index · China domestic market positioning
Western Analogs
Mental model only, not a 1:1 comparison
Founder
John V. Oyler
Founder & CEO
An American entrepreneur who partnered with Dr. Xiaodong Wang to build a borderless biotech company that could compete with the best in the West.